| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial
|
Westerhoff, Jasmijn Maria
|
|
|
9 |
8 |
p. 687
|
artikel
|
| 2 |
Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply
|
Timmer, Florentine E F
|
|
|
9 |
8 |
p. 687-688
|
artikel
|
| 3 |
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
|
Kang, Yoon-Koo
|
|
|
9 |
8 |
p. 705-717
|
artikel
|
| 4 |
Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease
|
Iacucci, Marietta
|
|
|
9 |
8 |
p. 758-772
|
artikel
|
| 5 |
Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B
|
Mak, Lung-Yi
|
|
|
9 |
8 |
p. 681-682
|
artikel
|
| 6 |
Considerations for treating autistic individuals in gastroenterology clinics
|
Buie, Timothy
|
|
|
9 |
8 |
p. 684-686
|
artikel
|
| 7 |
Digestive Disease Week 2024
|
Thomas, Hugh
|
|
|
9 |
8 |
p. 690
|
artikel
|
| 8 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
|
Oh, Do-Youn
|
|
|
9 |
8 |
p. 694-704
|
artikel
|
| 9 |
EASL Congress 2024
|
Brierley, Rob
|
|
|
9 |
8 |
p. 691
|
artikel
|
| 10 |
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma
|
Lowery, Maeve A
|
|
|
9 |
8 |
p. 679-681
|
artikel
|
| 11 |
Immunotherapy in biliary tract cancer: are we finally on the right path?
|
Ricci, Angela Dalia
|
|
|
9 |
8 |
p. 678-679
|
artikel
|
| 12 |
Infections in cirrhosis
|
Piano, Salvatore
|
|
|
9 |
8 |
p. 745-757
|
artikel
|
| 13 |
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
|
Vogel, Arndt
|
|
|
9 |
8 |
p. 734-744
|
artikel
|
| 14 |
Nanoliposomal irinotecan in advanced biliary tract cancers
|
Malka, David
|
|
|
9 |
8 |
p. 683-684
|
artikel
|
| 15 |
No accident: the UK infected blood scandal
|
The Lancet Gastroenterology & Hepatology,
|
|
|
9 |
8 |
p. 677
|
artikel
|
| 16 |
Research in Brief
|
Baker, Holly
|
|
|
9 |
8 |
p. 692
|
artikel
|
| 17 |
Saturated Facts: the start of a preventive revolution?
|
Haslam, Elizabeth
|
|
|
9 |
8 |
p. 693
|
artikel
|
| 18 |
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
|
Janssen, Harry L A
|
|
|
9 |
8 |
p. 718-733
|
artikel
|
| 19 |
Time for a treat all approach for hepatitis B
|
Halford, Rachel
|
|
|
9 |
8 |
p. 688-689
|
artikel
|
Tijdschrift beschrijving